Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is set for long-term success with continued positive sales growth driven by a strong commercialization strategy, increased placement of their robotic systems in BPH surgery centers, and the potential for international expansion. Despite some potential challenges such as handpiece sales and pricing pressure, the company's innovative technology and potential for addressing a larger market opportunity make it a strong investment opportunity. Additionally, the company's positive Q1 results and continued execution of their key strategies provide a strong foundation for future growth.

Bears say

PROCEPT BioRobotics is facing multiple challenges, including increasing competition in the BPH market and lower-than-expected handpiece sales driven by changes in purchasing patterns and inventory levels. This has led management to lower its 2026 revenue guidance and report weaker-than-expected Q4 results, with an adjusted EBITDA loss of $19 million. Despite the company's spot on domestic capital sales and record number of capital sales, there is still concern about the timeframe for sales force reorganization benefits to materialize, making it difficult for investors to ignore the impact of these challenges on PRCT's financials and outlook.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.